Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (VORVAX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02707900
Recruitment Status : Terminated (Manufacturing of the AGS-004 HIV vaccine by Argos could no longer be provided.)
First Posted : March 14, 2016
Last Update Posted : October 7, 2019
Sponsor:
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by (Responsible Party):
University of North Carolina, Chapel Hill

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : July 11, 2018
Actual Study Completion Date : July 11, 2018
Publications:
Sogaard O, Graversen ME, Leth S, Brinkmann C, Kjaer AS, Olesen R, et al. The HDAC inhibitor romidepsin is safe and effectively reverses HIV-1 latency in vivo as measured by standard clinical assays. In: 20th International AIDS Conference. Melbourne, Australia; 2014.
Debenedette M, Tcherepanova I, Gamble AH, Horatinovich J, Harris J, Routy JP, et al. Immune function and viral load post AGS-004 administration to chronic HIV subjects undergoing STI. In: 2014 Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2014.
Archin NM, Crooks AM, Bateson R, Cope AB, Dahl NP, Eron J, et al. Measuring HIV Latency Over Time: Reservoir Stability and Assessing Interventions. In: Conference on Retroviruses and Opportunistic Infections. Boston, MA; 2014.